Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?

  title={Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?},
  author={H. Mitsumoto and B. Brooks and V. Silani},
  journal={The Lancet Neurology},
  • H. Mitsumoto, B. Brooks, V. Silani
  • Published 2014
  • Medicine
  • The Lancet Neurology
  • Amyotrophic lateral sclerosis (ALS) is one of the most rapidly progressive neurodegenerative diseases of unknown cause. Riluzole is the only drug that slows disease progression. More than 50 randomised controlled trials (RCTs) of proposed disease-modifying drugs have failed to show positive results in the past half-century. In the past decade, at least 18 drugs have been tested in large phase 2 or 3 RCTs, including lithium, which was tested in several RCTs. Potential reasons for the negative… CONTINUE READING
    170 Citations
    The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future
    • 11
    Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials
    • 10
    Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection
    • 11
    Clinical trials in the ALS syndrome: it is time for change
    • M. Swash
    • Medicine
    • Journal of Neurology, Neurosurgery, and Psychiatry
    • 2019
    • 2
    Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs
    • 60
    Disease-modifying therapies in amyotrophic lateral sclerosis
    • 12


    Emerging drugs for amyotrophic lateral sclerosis
    • 40
    Preventing familial amyotrophic lateral sclerosis: Is a clinical trial feasible?
    • 19
    Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials
    • V. Meininger, G. Bensimon, +6 authors W. Robberecht
    • Medicine
    • Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases
    • 2004
    • 106